Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled flecainide for acute conversion of recent-onset paroxysmal atrial fibrillation
NL-OMON50703Phase 2Active, not recruiting
- Sponsor
- InCarda Therapeutics
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of flecainide in Atrial fibrillation (AFib) (7 arms), sponsored by InCarda Therapeutics. Primary endpoints: Feasibility endpoints, Conversion to sinus rhythm within 60 minutes and 1 more. Started Jun 2018; status: active, not recruiting.
02
Drugs
flecainide
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON50703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50703.